Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mamounas, E.
Right arrow Articles by Rockette, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mamounas, E.
Right arrow Articles by Rockette, H.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
Journal of Clinical Oncology, Vol 17, Issue 5 (May), 1999: 1349
© 1999 American Society for Clinical Oncology

Comparative Efficacy of Adjuvant Chemotherapy in Patients With Dukes' B Versus Dukes' C Colon Cancer: Results From Four National Surgical Adjuvant Breast and Bowel Project Adjuvant Studies (C-01, C-02, C-03, and C-04)

Eleftherios Mamounas, Samuel Wieand, Norman Wolmark, Harry D. Bear, James N. Atkins, Kyunghee Song, Judy Jones, Howard Rockette

From the National Surgical Adjuvant Breast and Bowel Project Operations and Biostatistical Centers, Pittsburgh, PA.

Address reprint requests to Norman Wolmark, MD, National Surgical Adjuvant Breast and Bowel Project, 4 Allegheny Center, 5th Floor, 320 E. North Ave, Pittsburgh, PA 15212

PURPOSE: Although the benefit from adjuvant chemotherapy has been clearly established in patients with Dukes' C colon cancer, such benefit has been questioned in patients with Dukes' B disease. To determine whether patients with Dukes' B disease benefit from adjuvant chemotherapy and to evaluate the magnitude of the benefit, compared with that observed in Dukes' C patients, we examined the relative efficacy of adjuvant chemotherapy according to Dukes' stage in four sequential National Surgical Adjuvant Breast and Bowel Project trials (C-01, C-02, C-03, and C-04) that compared different adjuvant chemotherapy regimens with each other or with no adjuvant treatment.

PATIENTS AND METHODS: The four trials included Dukes' B and C patients and were conducted between 1977 and 1990. The eligibility criteria and follow-up requirements were similar for all four trials. Protocol C-01 compared adjuvant semustine, vincristine, and fluorouracil (5-FU) (MOF regimen) with operation alone. Protocol C-02 compared the perioperative administration of a portal venous infusion of 5-FU with operation alone. Protocol C-03 compared adjuvant 5-FU and leucovorin (LV) with adjuvant MOF. Protocol C-04 compared adjuvant 5-FU and LV with 5-FU and levamisole (LEV) and with the combination of 5-FU, LV, and LEV.

RESULTS: Forty-one percent of the patients included in these four trials had resected Dukes' B tumors. In all four studies, the overall, disease-free, and recurrence-free survival improvement noted for all patients was evident in both Dukes' B and Dukes' C patients. When the relative efficacy of chemotherapy was examined, there was always an observed reduction in mortality, recurrence, or disease-free survival event, irrespective of Dukes' stage, and in most instances, the reduction was as great or greater for Dukes' B patients as for Dukes' C patients. When data from all four trials were examined in a combined analysis, the mortality reduction was 30% for Dukes' B patients versus 18% for Dukes' C patients. The mortality reduction in Dukes' B patients occurred irrespective of the presence or absence of adverse prognostic factors.

CONCLUSION: Patients with Dukes' B colon cancer benefit from adjuvant chemotherapy and should be presented with this treatment option. Regardless of the presence or absence of other clinical prognostic factors, Dukes' B patients seem to benefit from chemotherapy administration.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
M. Ychou, W. Hohenberger, S. Thezenas, M. Navarro, J. Maurel, C. Bokemeyer, E. Shacham-Shmueli, F. Rivera, C. Kwok-Keung Choi, and A. Santoro
A randomized phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer
Ann. Onc., June 30, 2009; (2009) mdp236v1.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. A. Waldman, T. Hyslop, S. Schulz, A. Barkun, K. Nielsen, J. Haaf, C. Bonaccorso, Y. Li, and D. S. Weinberg
Association of GUCY2C Expression in Lymph Nodes With Time to Recurrence and Disease-Free Survival in pN0 Colorectal Cancer
JAMA, February 18, 2009; 301(7): 745 - 752.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
H. Katsuno, E. Zacharakis, O. Aziz, C. Rao, S. Deeba, P. Paraskeva, P. Ziprin, T. Athanasiou, and A. Darzi
Does the Presence of Circulating Tumor Cells in the Venous Drainage of Curative Colorectal Cancer Resections Determine Prognosis? A Meta-Analysis
Ann. Surg. Oncol., November 1, 2008; 15(11): 3083 - 3091.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
Y. Jiang, G. Casey, I. C. Lavery, Y. Zhang, D. Talantov, M. Martin-McGreevy, M. Skacel, E. Manilich, A. Mazumder, D. Atkins, et al.
Development of a Clinically Feasible Molecular Assay to Predict Recurrence of Stage II Colon Cancer
J. Mol. Diagn., July 1, 2008; 10(4): 346 - 354.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Zlobec, L. M. Terracciano, and A. Lugli
Local Recurrence in Mismatch Repair-Proficient Colon Cancer Predicted by an Infiltrative Tumor Border and Lack of CD8+ Tumor-Infiltrating Lymphocytes
Clin. Cancer Res., June 15, 2008; 14(12): 3792 - 3797.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
R. N. Schwartz
Management of early and advanced colorectal cancer: Therapeutic issues
Am. J. Health Syst. Pharm., June 1, 2008; 65(11_Supplement_4): S8 - S14.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Berglund, B. Cedermark, and B. Glimelius
Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III?
Ann. Onc., February 1, 2008; 19(2): 400 - 402.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Zlobec, K. Baker, P. Minoo, J. R. Jass, L. Terracciano, and A. Lugli
Node-Negative Colorectal Cancer at High Risk of Distant Metastasis Identified by Combined Analysis of Lymph Node Status, Vascular Invasion, and Raf-1 Kinase Inhibitor Protein Expression
Clin. Cancer Res., January 1, 2008; 14(1): 143 - 148.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. J. Sargent, S. Patiyil, G. Yothers, D. G. Haller, R. Gray, J. Benedetti, M. Buyse, R. Labianca, J. F. Seitz, C. J. O'Callaghan, et al.
End Points for Colon Cancer Adjuvant Trials: Observations and Recommendations Based on Individual Patient Data From 20,898 Patients Enrolled Onto 18 Randomized Trials From the ACCENT Group
J. Clin. Oncol., October 10, 2007; 25(29): 4569 - 4574.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
B. M. Wolpin, J. A. Meyerhardt, H. J. Mamon, and R. J. Mayer
Adjuvant Treatment of Colorectal Cancer
CA Cancer J Clin, May 1, 2007; 57(3): 168 - 185.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
D. L. Bartlett, J. Berlin, G. Y. Lauwers, W. A. Messersmith, N. J. Petrelli, and A. P. Venook
Chemotherapy and Regional Therapy of Hepatic Colorectal Metastases: Expert Consensus Statement
Ann. Surg. Oncol., October 1, 2006; 13(10): 1284 - 1292.
[Full Text] [PDF]

Home page
 The OncologistHome page
A. B. Benson III
New Approaches to the Adjuvant Therapy of Colon Cancer
Oncologist, October 1, 2006; 11(9): 973 - 980.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
R. Luo, S. H. Giordano, J. L. Freeman, D. Zhang, and J. S. Goodwin
Referral to Medical Oncology: A Crucial Step in the Treatment of Older Patients with Stage III Colon Cancer
Oncologist, October 1, 2006; 11(9): 1025 - 1033.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
D. K. Monga and M. J. O'Connell
Surgical Adjuvant Therapy for Colorectal Cancer: Current Approaches and Future Directions
Ann. Surg. Oncol., August 1, 2006; 13(8): 1021 - 1034.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
R. C. G. Martin
Adjuvant Treatment of Stage II Colon Cancer: Is There a True No-Chemotherapy Group?
Ann. Surg. Oncol., June 1, 2006; 13(6): 766 - 767.
[Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
T. Andre, D. Sargent, J. Tabernero, M. O'Connell, M. Buyse, A. Sobrero, J.-L. Misset, C. Boni, and A. de Gramont
Current Issues in Adjuvant Treatment of Stage II Colon Cancer
Ann. Surg. Oncol., June 1, 2006; 13(6): 887 - 898.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. A. Walgren, M. A. Meucci, and H. L. McLeod
Pharmacogenomic Discovery Approaches: Will the Real Genes Please Stand Up?
J. Clin. Oncol., October 10, 2005; 23(29): 7342 - 7349.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Krajewska, H. Kim, C. Kim, H. Kang, K. Welsh, S.-i. Matsuzawa, M. Tsukamoto, R. G. Thomas, N. Assa-Munt, Z. Piao, et al.
Analysis of Apoptosis Protein Expression in Early-Stage Colorectal Cancer Suggests Opportunities for New Prognostic Biomarkers
Clin. Cancer Res., August 1, 2005; 11(15): 5451 - 5461.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Grothey and D. J. Sargent
FOLFOX for Stage II Colon Cancer? A Commentary on the Recent FDA Approval of Oxaliplatin for Adjuvant Therapy of Stage III Colon Cancer
J. Clin. Oncol., May 20, 2005; 23(15): 3311 - 3313.
[Full Text] [PDF]

Home page
 The OncologistHome page
L. Baddi and A. Benson III
Adjuvant Therapy in Stage II Colon Cancer: Current Approaches
Oncologist, May 1, 2005; 10(5): 325 - 331.
[Full Text] [PDF]

Home page
 The OncologistHome page
P. G. Johnston
Stage II Colorectal Cancer: To Treat or not to Treat
Oncologist, May 1, 2005; 10(5): 332 - 334.
[Full Text] [PDF]

Home page
 INT J SURG PATHOLHome page
S. Popat, R. Wort, and R. S. Houlston
Relationship Between Thymidylate Synthase (TS) Genotype and TS Expression: A Tissue Microarray Analysis of Colorectal Cancers
International Journal of Surgical Pathology, April 1, 2005; 13(2): 127 - 133.
[Abstract] [PDF]

Home page
 JCOHome page
E. A. Poplin, J. K. Benedetti, N. C. Estes, D. G. Haller, R. J. Mayer, R. M. Goldberg, G. R. Weiss, S. E. Rivkin, and J. S. Macdonald
Phase III Southwest Oncology Group 9415/Intergroup 0153 Randomized Trial of Fluorouracil, Leucovorin, and Levamisole Versus Fluorouracil Continuous Infusion and Levamisole for Adjuvant Treatment of Stage III and High-Risk Stage II Colon Cancer
J. Clin. Oncol., March 20, 2005; 23(9): 1819 - 1825.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
J. A. Meyerhardt and R. J. Mayer
Systemic Therapy for Colorectal Cancer
N. Engl. J. Med., February 3, 2005; 352(5): 476 - 487.
[Full Text] [PDF]

Home page
 JCOHome page
S. Popat, R. Hubner, and R.S. Houlston
Systematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
J. Clin. Oncol., January 20, 2005; 23(3): 609 - 618.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
A. Zaniboni and R. Labianca
Adjuvant therapy for stage II colon cancer: an elephant in the living room?
Ann. Onc., September 1, 2004; 15(9): 1310 - 1318.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Figueredo, M. L. Charette, J. Maroun, M. C. Brouwers, and L. Zuraw
Adjuvant Therapy for Stage II Colon Cancer: A Systematic Review From the Cancer Care Ontario Program in Evidence-Based Care's Gastrointestinal Cancer Disease Site Group
J. Clin. Oncol., August 15, 2004; 22(16): 3395 - 3407.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
T. Andre, C. Boni, L. Mounedji-Boudiaf, M. Navarro, J. Tabernero, T. Hickish, C. Topham, M. Zaninelli, P. Clingan, J. Bridgewater, et al.
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
N. Engl. J. Med., June 3, 2004; 350(23): 2343 - 2351.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Gill, C. L. Loprinzi, D. J. Sargent, S. D. Thome, S. R. Alberts, D. G. Haller, J. Benedetti, G. Francini, L. E. Shepherd, J. Francois Seitz, et al.
Pooled Analysis of Fluorouracil-Based Adjuvant Therapy for Stage II and III Colon Cancer: Who Benefits and by How Much?
J. Clin. Oncol., May 15, 2004; 22(10): 1797 - 1806.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
Y. Wang, T. Jatkoe, Y. Zhang, M. G. Mutch, D. Talantov, J. Jiang, H. L. McLeod, and D. Atkins
Gene Expression Profiles and Molecular Markers To Predict Recurrence of Dukes' B Colon Cancer
J. Clin. Oncol., May 1, 2004; 22(9): 1564 - 1571.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
Efficacy of Oral Adjuvant Therapy After Resection of Colorectal Cancer: 5-Year Results From Three Randomized Trials
J. Clin. Oncol., February 1, 2004; 22(3): 484 - 492.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Popat, A. Matakidou, and R. S. Houlston
Thymidylate Synthase Expression and Prognosis in Colorectal Cancer: A Systematic Review and Meta-Analysis
J. Clin. Oncol., February 1, 2004; 22(3): 529 - 536.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
J M Garcia, R Rodriguez, G Dominguez, J M Silva, M Provencio, J Silva, A Colmenarejo, I Millan, C Munoz, C Salas, et al.
Prognostic significance of the allelic loss of the BRCA1 gene in colorectal cancer
Gut, December 1, 2003; 52(12): 1756 - 1763.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
T. Andre, P. Colin, C. Louvet, E. Gamelin, O. Bouche, E. Achille, N. Colbert, C. Boaziz, P. Piedbois, N. Tubiana-Mathieu, et al.
Semimonthly Versus Monthly Regimen of Fluorouracil and Leucovorin Administered for 24 or 36 Weeks as Adjuvant Therapy in Stage II and III Colon Cancer: Results of a Randomized Trial
J. Clin. Oncol., August 1, 2003; 21(15): 2896 - 2903.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
A. Bilchik
More (Nodes) + More (Analysis) = Less (Mortality): Challenging the Therapeutic Equation for Early-Stage Colon Cancer
Ann. Surg. Oncol., April 1, 2003; 10(3): 203 - 205.
[Full Text] [PDF]

Home page
 Ann OncolHome page
H. T. Arkenau, A. Bermann, K. Rettig, G. Strohmeyer, and R. Porschen
5-Fluorouracil plus leucovorin is an effective adjuvant chemotherapy in curatively resected stage III colon cancer: long-term follow-up results of the adjCCA-01 trial
Ann. Onc., March 1, 2003; 14(3): 395 - 399.
[Abstract] [Full Text] [PDF]

Home page
 Br Med BullHome page
I. Chau and D. Cunningham
Chemotherapy in colorectal cancer: new options and new challenges
Br. Med. Bull., December 1, 2002; 64(1): 159 - 180.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Schrag, S. Rifas-Shiman, L. Saltz, P. B. Bach, and C. B. Begg
Adjuvant Chemotherapy Use for Medicare Beneficiaries With Stage II Colon Cancer
J. Clin. Oncol., October 1, 2002; 20(19): 3999 - 4005.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Iacopetta
A biological perspective on the selection of stage II colorectal cancer patients for adjuvant chemotherapy
Ann. Onc., September 1, 2002; 13(9): 1510 - 1510.
[Full Text] [PDF]

Home page
 GutHome page
G T Williams
A long hard look at Dukes' B
Gut, July 1, 2002; 51(1): 6 - 7.
[Full Text]

Home page
 GutHome page
V C Petersen, K J Baxter, S B Love, and N A Shepherd
Identification of objective pathological prognostic determinants and models of prognosis in Dukes' B colon cancer
Gut, July 1, 2002; 51(1): 65 - 69.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.E. Tepper, M. O'Connell, D. Niedzwiecki, D.R. Hollis, A.B. Benson III, B. Cummings, L.L. Gunderson, J.S. Macdonald, J.A. Martenson, and R.J. Mayer
Adjuvant Therapy in Rectal Cancer: Analysis of Stage, Sex, and Local Control--Final Report of Intergroup 0114
J. Clin. Oncol., April 1, 2002; 20(7): 1744 - 1750.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. L. Potosky, L. C. Harlan, R. S. Kaplan, K. A. Johnson, and C. F. Lynch
Age, Sex, and Racial Differences in the Use of Standard Adjuvant Therapy for Colorectal Cancer
J. Clin. Oncol., March 1, 2002; 20(5): 1192 - 1202.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
F. Perrone, C. Gallo, B. Daniele, R. J. Nauta, J. L. Warren, M. L. Brown, D. J. Sargent, R. M. Goldberg, and S. D. Jacobson
Chemotherapy in the Elderly
N. Engl. J. Med., February 21, 2002; 346(8): 622 - 623.
[Full Text] [PDF]

Home page
 NEJMHome page
D. J. Sargent, R. M. Goldberg, S. D. Jacobson, J. S. Macdonald, R. Labianca, D. G. Haller, L. E. Shepherd, J. F. Seitz, and G. Francini
A Pooled Analysis of Adjuvant Chemotherapy for Resected Colon Cancer in Elderly Patients
N. Engl. J. Med., October 11, 2001; 345(15): 1091 - 1097.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. Porschen, A. Bermann, T. Loffler, G. Haack, K. Rettig, Y. Anger, and G. Strohmeyer
Fluorouracil Plus Leucovorin as Effective Adjuvant Chemotherapy in Curatively Resected Stage III Colon Cancer: Results of the Trial adjCCA-01
J. Clin. Oncol., March 15, 2001; 19(6): 1787 - 1794.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Cascinu, M. P. Staccioli, G. Gasparini, P. Giordani, V. Catalano, R. Ghiselli, C. Rossi, A. M. Baldelli, F. Graziano, V. Saba, et al.
Expression of Vascular Endothelial Growth Factor Can Predict Event-free Survival in Stage II Colon Cancer
Clin. Cancer Res., July 1, 2000; 6(7): 2803 - 2807.
[Abstract] [Full Text]

Home page
 JCOHome page
J. R. Hoverman and S. W. N. Wolmark
The Logic of Evidence
J. Clin. Oncol., February 1, 2000; 18(4): 942 - 942.
[Full Text] [PDF]

Home page
 JCOHome page
H. O. Douglass Jr
Results From National Surgical Adjuvant Breast and Bowel Project Colon Cancer Trials
J. Clin. Oncol., January 5, 2000; 18(1): 235 - 235.
[Full Text] [PDF]

Home page
 JCOHome page
J.-P. P. M. Ducreux, P. Rougier, and C. Erlichman
More Patients Needed in Stage II Colon Cancer Trials
J. Clin. Oncol., January 5, 2000; 18(1): 235 - 235.
[Full Text]

Home page
 JNCI J Natl Cancer InstHome page
K. C. Halling, A. J. French, S. K. McDonnell, L. J. Burgart, D. J. Schaid, B. J. Peterson, L. Moon-Tasson, M. R. Mahoney, D. J. Sargent, M. J. O'Connell, et al.
Microsatellite Instability and 8p Allelic Imbalance in Stage B2 and C Colorectal Cancers
J Natl Cancer Inst, August 4, 1999; 91(15): 1295 - 1303.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. P. Harrington
The Tea Leaves of Small Trials
J. Clin. Oncol., May 1, 1999; 17(5): 1336 - 1336.
[Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 1999 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online